Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: J Thorac Oncol. 2018 Jul 11;13(10):1595–1601. doi: 10.1016/j.jtho.2018.07.004

Figure 2. Survival with multikinase inhibition in RET-rearranged lung cancers with intracranial disease.

Figure 2.

Kaplan-Meier progression-free survival (PFS) and overall survival (OS) curves of patients with stage IV, RFT-rearranged lung cancers treated with multikinase inhibitors are shown. The PFS and OS of patients with brain metastases prior to tyrosine kinase inhibitor (TKI) therapy were compared to patients without baseline brain metastases.